Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

PURPOSE: Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESMO Open
Main Authors: Morgillo, Floriana, Fasano, Morena, Della Corte, Carminia Maria, Sasso, Ferdinando Carlo, Papaccio, Federica, Viscardi, Giuseppe, Esposito, Giovanna, Di Liello, Raimondo, Normanno, Nicola, Capuano, Annalisa, Berrino, Liberato, Vicidomini, Giovanni, Fiorelli, Alfonso, Santini, Mario, Ciardiello, Fortunato
Formato: Artigo
Idioma:Inglês
Publicado em: ESMO Open 2017
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5519802/
https://ncbi.nlm.nih.gov/pubmed/28761738
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000132
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados